Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07184931 · ClinicalTrials.gov registry record · Phase 3
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
A Phase 3 study of Crohn's Disease, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 980
- Enrollment target
- 20
- Study locations
NCT07184931 is a Phase 3 study of Crohn's Disease that is actively recruiting participants, run by Sanofi. The registered enrollment target is 980 participants, below the 2,405-participant average among 104 other Crohn's Disease trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT07184931, a Phase 3 study of Crohn's Disease, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 980 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active CD. Study details include: The study duration may be up to 35 weeks with: * Up to 5-week Screening Period. * 12-week Sub-Study 1 (Single Arm Open-Label Feeder Induction) or Sub-Study 2 (Pivotal Induction). * 12-week Sub-Study 3 (Extended Induction for non-responders). * 6 weeks (45 days) follow-up period for participants who do not enroll into the Pivotal Maintenance Study (EFC18327). The treatment duration will be up to 12 weeks in each sub-study. The number of scheduled study visits for participants who continue to the Pivotal Maintenance Study (EFC18327) will be up to 8 (Sub-Study 1 and Sub-Study 2) and up to 15 for participants who enroll in Sub-Study 3.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Duvakitug
Study Locations (20)
California
- Kagoshima IBD Gastroenterology Clinic - Site Number: 8400008 - Canoga Park
- Southern California GI & Liver Centers-Site Number: 8400062 - Coronado
- GMC Clinical Research, LLC-Site Number: 8400113 - Folsom
- TLC Clinical Research Inc.: 8400030 - Los Angeles
- United Medical Doctors CA-Site Number: 8400044 - Murrieta
- Prospective Research Innovations Inc.: 8400017 - Rancho Cucamonga
- Valiance Clinical Research - Tarzana: 8400023 - Tarzana
- Clinical Trials Management Services-Site Number: 8400047 - Thousand Oaks
- Amicis Research Center-Valencia-Site Number: 8400064 - Valencia
- Om Research, LLC - Victorville - Site Number: 8400022 - Victorville
Florida
- Precision Clinical Research: 8400059 - Coral Springs
- Sarkis Clinical Trials-Ocala-Site Number: 8400048 - Gainesville
- Clinical Research of Osceola-Site Number: 8400013 - Kissimmee
- Columbus Clinical Services LLc-Site Number: 8400038 - Miami
- Regis Clinical Research, LLC-Site Number: 8400041 - Miami
Arizona
- Onyx Clinical Research - Site Number: 8400021 - Peoria
- One of a Kind Clinical Research Center LLC-Site Number: 8400061 - Scottsdale
- Del Sol Research Management, LLC-Site Number: 8400012 - Tucson
Arkansas
- Preferred Research Partners: 8400018 - Little Rock
Colorado
- Peak Gastroenterology Associates - Colorado Springs-Site Number: 8400039 - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 980 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2029-05-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07184931
The ClinicalTrials.gov registry entry for NCT07184931 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 980 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,405-participant average among 104 other Crohn's Disease trials with a reported enrollment target (59% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07184931 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT07184931 about?
NCT07184931 is a clinical study titled "An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease". This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active CD. Study details include: The study duration may be up to 35 ...
What is the current status of trial NCT07184931?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 980 participants. The study started on 2025-10-01. Estimated completion is 2029-05-14.
What conditions does trial NCT07184931 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT07184931?
The interventions under investigation include: Placebo (DRUG), Duvakitug (DRUG).
Who is sponsoring clinical trial NCT07184931?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07184931 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
RECRUITING · Phase 3
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RECRUITING · Phase 3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
-
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.